Drug Approval | March 21, 2022
Zydus receives PAS approval for Mycophenolate Mofetil
The drug is indicated for use in combination with other drugs
The drug is indicated for use in combination with other drugs
The facility will produce 150 million vaccine doses per year
The company plans to launch the product immediately
Sputnik Light is the first component of Sputnik V
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
Subscribe To Our Newsletter & Stay Updated
